Independent Research
TEM Analysis
4 pieces of research on Tempus AI, Inc.. We find the signal management buried in the earnings call.
Tempus AI CEO Sells $7.7M After Material Agreement
Tempus AI CEO Eric Lefkofsky and four other executives sold a combined $10.3 million in shares during May 2026, following a Material Definitive Agreement filing…
Read analysis →Tempus AI Grew Revenue 83% But Is Still Burning $112 Million a Year in Cash
Tempus AI's four consecutive EPS beats and 83% revenue growth have Wall Street setting a $75 target, but free cash flow remains -$112M. The narrowing GAAP loss …
Read analysis →Tempus AI Posts 83% Revenue Growth, Stock Drops 7% Anyway
Tempus AI beat earnings estimates and announced a major USC partnership covering 1.5 million patient visits, but shares fell 7% as the stock's lofty valuation l…
Read analysis →Tempus AI Surges 30% in a Week on Cancer Test Launch, but Trades at -618x Earnings
Tempus AI surged 30% in a week on a new cancer test kit and a genomics partnership with Predicta Biosciences, but the stock trades at a deeply negative forward …
Read analysis →